STACKD summary
Limited human dataSS-31 (elamipretide) and MOTS-c: mitochondria-targeted peptides
One has an FDA approval for a rare disease; the other is still almost entirely mouse biology.
Plain-language summary
SS-31 and MOTS-c are grouped together because both target mitochondria, the cell's energy-producing structures, but they work in different ways and sit at very different points in the evidence pipeline. SS-31 (elamipretide) binds a specific membrane lipid called cardiolipin and stabilizes it, and it's real enough that it earned FDA approval in 2024 as a treatment for Barth syndrome, a rare genetic mitochondrial disease. MOTS-c is a tiny peptide encoded inside mitochondrial DNA itself, tied in animal studies to insulin sensitivity and resistance to diet-induced weight gain. The gap between them matters: one has randomized human trial data behind an actual drug label, the other's exciting findings are still confined to mice.
What was studied
For SS-31, the TAZPOWER program: a randomized, placebo-controlled trial followed by a 168-week open-label extension in Barth syndrome patients, plus mechanistic work on isolated aged mitochondria. For MOTS-c, foundational and follow-up animal studies on metabolic homeostasis, insulin sensitivity, and AMPK-pathway signaling, summarized in a 2022 review of mitochondrial-derived peptides in human aging.
Key takeaways
- SS-31/elamipretide is one of the few mitochondria-targeted compounds with an actual FDA approval, specifically for Barth syndrome, a rare genetic cardiolipin disorder, not for general aging or fitness use.
- The pivotal SS-31 trial's short randomized phase missed its primary endpoints; the case for benefit rests substantially on the longer open-label extension, which lacks a placebo comparison over that period.
- MOTS-c's metabolic benefits (better insulin sensitivity, resistance to diet-induced obesity) are consistently reported in mice but have not been tested in a comparable human trial.
- Both peptides work through mitochondrial mechanisms that are biologically distinct: SS-31 stabilizes a membrane lipid directly, while MOTS-c is thought to act through AMPK-related nuclear signaling after cellular stress.
Limitations & what we don't know
- SS-31's approval is narrow (a specific rare disease with a defined molecular abnormality) and should not be read as validation for the compound's off-label aging or recovery use.
- MOTS-c has no large human RCT comparable to what exists for SS-31; nearly everything published is rodent or cell-culture work.
- The mouse-to-human translational gap for MOTS-c is large and unresolved, a pattern common across mitochondrial-derived peptide research.
- Both compounds are discussed heavily in longevity and biohacking circles for uses well beyond what their actual trial data supports.
Sources
Primary citations behind this summary. External links are provided for verification, read them yourself before drawing conclusions.